Complement pathway inhibitors binding to C5 and C5a without preventing formation of C5b
US7432356B2 · kind B2 · utility
45Cited by
1References
12Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Aug 17, 2002 |
| Grant date | Oct 7, 2008 |
| Priority date | — |
| Expiry date | Dec 20, 2022 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/94
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention relates to inhibitors that bind to C5 and C5a, but which do not prevent the activation of C5 and do not prevent formation of or inhibit the activity of C5b. One example of such an inhibitor molecule is the monoclonal antibody designated MAb137-26, which binds to a shared epitope of human C5 and C5a. These inhibitors may be used to inhibit the activity of C5a in treating diseases and conditions mediated by excessive or uncontrolled production of C5a. The inhibitor molecules are also useful for diagnostic detection of the presence/absence or amount of C5 or C5a.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.